129 related articles for article (PubMed ID: 29106549)
1. The in Vitro Actions of Loxapine on Dopaminergic and Serotonergic Receptors. Time to Consider Atypical Classification of This Antipsychotic Drug?
Ferreri F; Drapier D; Baloche E; Ouzid M; Zimmer L; Llorca PM
Int J Neuropsychopharmacol; 2018 Apr; 21(4):355-360. PubMed ID: 29106549
[TBL] [Abstract][Full Text] [Related]
2. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes.
Singh AN; Barlas C; Singh S; Franks P; Mishra RK
J Psychiatry Neurosci; 1996 Jan; 21(1):29-35. PubMed ID: 8580115
[TBL] [Abstract][Full Text] [Related]
3. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia.
Kapur S; Zipursky R; Remington G; Jones C; McKay G; Houle S
Am J Psychiatry; 1997 Nov; 154(11):1525-9. PubMed ID: 9356559
[TBL] [Abstract][Full Text] [Related]
4. Do loxapine plus cyproheptadine make an atypical antipsychotic? PET analysis of their dopamine D2 and serotonin2 receptor occupancy.
Kapur S; Zipursky RB
Arch Gen Psychiatry; 1998 Jul; 55(7):666-8. PubMed ID: 9672060
[No Abstract] [Full Text] [Related]
5. Does loxapine have "atypical" properties? Clinical evidence.
Glazer WM
J Clin Psychiatry; 1999; 60 Suppl 10():42-6. PubMed ID: 10340686
[TBL] [Abstract][Full Text] [Related]
6. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
7. Introduction: What makes an antipsychotic atypical?
Stahl SM
J Clin Psychiatry; 1999; 60 Suppl 10():3-4. PubMed ID: 10340681
[No Abstract] [Full Text] [Related]
8. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.
Shahid M; Walker GB; Zorn SH; Wong EH
J Psychopharmacol; 2009 Jan; 23(1):65-73. PubMed ID: 18308814
[TBL] [Abstract][Full Text] [Related]
9. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor.
Rauser L; Savage JE; Meltzer HY; Roth BL
J Pharmacol Exp Ther; 2001 Oct; 299(1):83-9. PubMed ID: 11561066
[TBL] [Abstract][Full Text] [Related]
10. From anti-allergic to anti-Alzheimer's: Molecular pharmacology of Dimebon.
Okun I; Tkachenko SE; Khvat A; Mitkin O; Kazey V; Ivachtchenko AV
Curr Alzheimer Res; 2010 Mar; 7(2):97-112. PubMed ID: 19939222
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic.
Ereshefsky L
J Clin Psychiatry; 1999; 60 Suppl 10():20-30. PubMed ID: 10340684
[TBL] [Abstract][Full Text] [Related]
12. Serotonin receptors: their key role in drugs to treat schizophrenia.
Meltzer HY; Li Z; Kaneda Y; Ichikawa J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
[TBL] [Abstract][Full Text] [Related]
13. The D2 receptor occupancy profile of loxapine determined using PET.
Kapur S; Zipursky RB; Jones C; Remington GJ; Wilson AA; DaSilva J; Houle S
Neuropsychopharmacology; 1996 Dec; 15(6):562-6. PubMed ID: 8946430
[TBL] [Abstract][Full Text] [Related]
14. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
15. The role of alpha2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat.
Kalkman HO; Neumann V; Hoyer D; Tricklebank MD
Br J Pharmacol; 1998 Aug; 124(7):1550-6. PubMed ID: 9723970
[TBL] [Abstract][Full Text] [Related]
16. Contrasting loxapine to its isomer isoloxapine--the critical role of in vivo D2 blockade in determining atypicality.
Natesan S; Vanderspek S; Nobrega JN; McClelland RA; Kapur S
Schizophr Res; 2005 Sep; 77(2-3):189-99. PubMed ID: 15925489
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and binding affinity of potential atypical antipsychotics with the tetrahydroquinazolinone motif.
Carro L; Raviña E; Domínguez E; Brea J; Loza MI; Masaguer CF
Bioorg Med Chem Lett; 2009 Nov; 19(21):6059-62. PubMed ID: 19796944
[TBL] [Abstract][Full Text] [Related]
18. Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia.
Singh AN; Barlas C; Saeedi H; Mishra RK
J Psychiatry Neurosci; 2003 Jan; 28(1):39-47. PubMed ID: 12587849
[TBL] [Abstract][Full Text] [Related]
19. Syntheses, radiolabelings, and in vitro evaluations of fluorinated PET radioligands of 5-HT6 serotoninergic receptors.
Colomb J; Becker G; Fieux S; Zimmer L; Billard T
J Med Chem; 2014 May; 57(9):3884-90. PubMed ID: 24754711
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride.
Rabiner EA; Gunn RN; Wilkins MR; Sedman E; Grasby PM
J Psychopharmacol; 2002 Sep; 16(3):195-9. PubMed ID: 12236624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
